Veeva Systems and BioMarin Pharmaceutical have signed a five-year enterprise agreement to standardize clinical, regulatory and quality operations on Veeva’s Vault platform. Under the deal, BioMarin will deploy more than 20 Vault applications across clinical data management, regulatory submissions and quality oversight, consolidating legacy point solutions and reducing IT maintenance by an estimated 25%. The partnership is expected to accelerate BioMarin’s clinical trial start-up times by up to 30%, while delivering compliance efficiencies that could shave six weeks off annual regulatory filing cycles.

Truist Securities raised its recommendation on Veeva Systems to Buy from Hold and established a $275.00 target, citing a diminished CRM concentration—now representing roughly 30% of total revenue—and deferred migration headwinds pushed beyond fiscal 2027. The firm highlighted Veeva’s Rule of 60 compliance, noting subscription revenue growth of 18% year-over-year and an adjusted EBITDA margin north of 45%. Truist also lauded 40% growth in the Crossix data analytics segment and early traction in artificial intelligence offerings as drivers of durable top-line expansion and margin stability.

On January 8, 2026, Veeva announced Veeva Environmental Monitoring, a cloud-native application integrated with Veeva LIMS and part of the Veeva Quality Cloud suite. The solution automates scheduling, collection and analysis of environmental samples to ensure GMP and internal sterility compliance, eliminating paper-based workflows and data silos. Scheduled for general availability in December 2026, the module will interoperate with Veeva QMS and QualityDocs, automatically triggering quality events and publishing key monitoring data to Veeva Batch Release—reducing release cycle times by an estimated 20% in early adopters.